Donald Castell to Cross-Over Studies
This is a "connection" page, showing publications Donald Castell has written about Cross-Over Studies.
Connection Strength
0.858
-
Concomitant Administration of a Histamine2 Receptor Antagonist and Proton Pump Inhibitor Enhances Gastric Acid Suppression. Pharmacotherapy. 2015 Dec; 35(12):1124-9.
Score: 0.123
-
Arbaclofen placarbil decreases postprandial reflux in patients with gastroesophageal reflux disease. Am J Gastroenterol. 2010 Jun; 105(6):1266-75.
Score: 0.081
-
The effect of oral buspirone, pyridostigmine, and bethanechol on esophageal function evaluated with combined multichannel esophageal impedance-manometry in healthy volunteers. J Clin Gastroenterol. 2009 Mar; 43(3):253-60.
Score: 0.077
-
Comparison of the effects of immediate-release omeprazole powder for oral suspension and pantoprazole delayed-release tablets on nocturnal acid breakthrough in patients with symptomatic gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2005 Jun 15; 21(12):1467-74.
Score: 0.059
-
Dose-dependent control of intragastric pH by pantoprazole, 10, 20 or 40 mg, in healthy volunteers. Aliment Pharmacol Ther. 2002 Apr; 16(4):829-36.
Score: 0.048
-
Over-the-counter H(2)-receptor antagonists do not compromise intragastric pH control with proton pump inhibitors. Aliment Pharmacol Ther. 2002 Mar; 16(3):473-7.
Score: 0.047
-
Control of intragastric pH with omeprazole 20 mg, omeprazole 40 mg and lansoprazole 30 mg. Aliment Pharmacol Ther. 2001 May; 15(5):647-52.
Score: 0.045
-
Proton pump inhibitors: better acid suppression when taken before a meal than without a meal. Aliment Pharmacol Ther. 2000 Oct; 14(10):1267-72.
Score: 0.043
-
Gastric acidity and acid breakthrough with twice-daily omeprazole or lansoprazole. Aliment Pharmacol Ther. 2000 Jun; 14(6):709-14.
Score: 0.042
-
Post-prandial ranitidine is superior to post-prandial omeprazole in control of gastric acidity in healthy volunteers. Aliment Pharmacol Ther. 1999 Sep; 13(9):1211-4.
Score: 0.040
-
Bedtime ranitidine does not eliminate the need for a second daily dose of omeprazole to suppress nocturnal gastric pH. Aliment Pharmacol Ther. 1999 May; 13(5):675-8.
Score: 0.039
-
Ranitidine controls nocturnal gastric acid breakthrough on omeprazole: a controlled study in normal subjects. Gastroenterology. 1998 Dec; 115(6):1335-9.
Score: 0.038
-
Nocturnal gastric acidity and acid breakthrough on different regimens of omeprazole 40 mg daily. Aliment Pharmacol Ther. 1998 Dec; 12(12):1235-40.
Score: 0.038
-
Imipramine decreases oesophageal pain perception in human male volunteers. Gut. 1998 Jun; 42(6):807-13.
Score: 0.037
-
Dual site ambulatory pH monitoring: a probe across the lower esophageal sphincter does not induce gastroesophageal reflux. Am J Gastroenterol. 1996 Jun; 91(6):1162-6.
Score: 0.032
-
Diagnosis of Esophageal Motility Disorders: Esophageal Pressure Topography vs. Conventional Line Tracing. Am J Gastroenterol. 2015 Jul; 110(7):967-77; quiz 978.
Score: 0.030
-
Intragastric acidity after switching from 5-day treatment with intravenous pantoprazole 40 mg/d to 5-day treatment with oral esomeprazole 40 mg/d or pantoprazole 40 mg/d: an open-label crossover study in healthy adult volunteers. Clin Ther. 2006 May; 28(5):725-33.
Score: 0.016
-
Intragastric acid suppression and pharmacokinetics of twice-daily esomeprazole: a randomized, three-way crossover study. Aliment Pharmacol Ther. 2004 Aug 15; 20(4):399-406.
Score: 0.014
-
The effects of tegaserod (HTF 919) on oesophageal acid exposure in gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2000 Nov; 14(11):1503-9.
Score: 0.011